December 2025– date –
-
From Beginner to Expert | Aging and Cancer Introductory Series – Part 2 How Aging and Cancer Are Linked at the Molecular and Genetic Levels
Introduction: Zooming in on the “Inner Structure” of Aging In Part 1, we asked why cancer is often called a “disease of aging” and reviewed how the hallmarks of aging and the hallmarks of cancer overlap. We moved beyond the simple idea t... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 1 Why Is Cancer Called a “Disease of Aging”?
Introduction: Why Revisit “Aging and Cancer” Now? The phrase “cancer is a disease of aging” is something most clinicians and life science professionals have heard countless times. Yet very few of us have had the chance to carefully organ... -
Recent ADC Landscape Update Series, Part 3: Merck–Daiichi’s CDH6 ADC R-DXd and DLL3 ADC SHR-4849 – The Next Wave in Ovarian Cancer and SCLC
In Part 3 of this series, we focus on two “second-wave” ADC programs that have attracted considerable attention over the past few months: raludotatug deruxtecan (R-DXd), a CDH6-targeted DXd ADC being co-developed by Daiichi Sankyo a... -
Recent ADC Landscape Update Series, Part 2: Enhertu in Early HER2-Positive Breast Cancer – What DESTINY-Breast05 and 11 Mean for Future Standards of Care
In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-based ADC from AstraZeneca and Daiichi Sankyo that has already transformed the treatment of advanced HER2-positive and HER2-low breast cancer. At ESMO&n... -
Recent ADC Landscape Update Series, Part 1: AstraZeneca’s Post-Enhertu Strategy – In-house ADCs, Radiopharma and Cell Therapy to Redefine Oncology
Around 2025, oncology is entering a new phase in which antibody–drug conjugates (ADCs) sit at the center of a much broader competition for the “next decade” of cancer care. In this series, we review the most important recent clinical dat... -
Oncology Drug Approval News Flash：FDA approves lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma
On December 4, 2025, the U.S. Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol Myers Squibb company), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or ref... -
Big Pharma Mega Deals in the Last Few Months Series Part 6 | A Startup-Side Playbook: Building a Company That Can Partner or Stay Independent
In the previous installments of this series, we looked at recent big pharma transactions through the lenses of oncology, obesity/metabolic disease, respiratory and infectious disease, and finally from an investor’s point of view. In this... -
Oncology Drug Approval News Flash：FDA grants traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory CLL/SLL after covalent BTK inhibitor therapy
On December 3, 2025, the U.S. Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic l... -
Big Pharma Mega Deals in the Last Few Months Series Part 5 | How Investors Can Read and Use Big Pharma Transactions
When investors follow big pharma transactions, it is tempting to focus on headline numbers: total deal value, takeover premium, “multi-billion” labels. Those figures certainly make for eye-catching news, but they do not tell the full sto... -
Big Pharma Mega Deals in the Last Few Months Series Part 4 | Respiratory and Infectious Disease: From COPD and Rare Lung Disorders to Seasonal Viral Threats
Alongside oncology and metabolic disease, one of the most striking clusters in recent big pharma transactions over the last few months is respiratory and infectious disease. Chronic obstructive pulmonary disease (COPD), asthma, rare lung... -
Big Pharma Mega Deals in the Last Few Months Series Part 3 | Obesity, MASH and Metabolic Disease: Beyond the GLP-1 Wave toward Integrated CVRM Strategy
When we look at the big pharma transactions announced over the last few months, oncology is an obvious hot spot. But right next to it, in terms of strategic importance and deal size, we find a cluster centered on obesity, MASH and metabo...
12